Clinical trial
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00069901 |
|---|---|
| Title | Phase II CT-2103/Carboplatin in Ovarian Cancer |
| Official title | CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasm |
| Intervention type | Drug |
| Interventions | CT-2103 (poly(L)glutamate-paclitaxel), carboplatin |
| Enrollment | 82 |
| Start date | Feb 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Oct 6, 2003 |
| Last update posted | Sep 22, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: